Skip to content

Common Stock at other companies

Glaukos logo
GlaukosGKOS
$58K+1.8%
AbbVie logo
AbbVieABBV
$18M0.0%
Schering-Plough logo
Schering-PloughSGP
154.4M0.0%
Bausch + Lomb logo
Bausch + LombBLCO
$0
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
200M0.0%

Other financials

Income statement

See full
Revenue$19.7M+12.5%
Gross profit$17.0M+12.5%
Operating income-$12.4M+10.4%
Net income-$13.0M+8.3%
EPS (diluted)-$0.24+14.3%

Balance sheet

See full
Cash & equivalents$85.0M-21.9%
Total debt$40.9M+1.1%
Total equity$53.9M-30.6%
Total assets$109.7M-15.4%

Cash flow

See full
Operating cash flow-$7.0M+39.4%
CapEx$60.0K
Free cash flow-$7.1M+38.9%

Valuation

See full
Market cap$294.9M+35.0%
Enterprise value$250.83M+59.0%
P/S3.7×+0.8×

Profitability

See full
Gross margin86.2%+0.5pp
Operating margin-44.8%-10.2pp
Net margin-46.8%-9.6pp
FCF margin-31.9%+0.2pp

Returns & leverage

See full
Return on equity-56.6%+4.3pp
Debt / equity0.8×+0.2×
Current ratio5.9×-4.6×

Where this comes from

Reported directly by Sight Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: Sight Sciences, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sight Sciences, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sight Sciences, Inc.'s common stock?
Sight Sciences, Inc. (SGHT) reported common stock of $54K in Q1 2026.
How has Sight Sciences, Inc.'s common stock changed year-over-year?
Sight Sciences, Inc.'s common stock increased by 5.9% year-over-year, from $51K to $54K.
What is the long-term trend for Sight Sciences, Inc.'s common stock?
Over 5 years (2020 to 2025), Sight Sciences, Inc.'s common stock has grown at a 43.1% compound annual growth rate (CAGR), from $9K to $54K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).